Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
DA Sychev, NP Denisenko, ZM Sizova, AV Grachev & KA Velikolug. (2015) The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmacogenomics and Personalized Medicine 8, pages 111-114.
Read now
Read now
YoonJung Choi, HyeKyung Han, Dongseong Shin, Kyoung Soo Lim & Kyung-Sang Yu. (2015) Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. Drug Design, Development and Therapy 9, pages 4127-4135.
Read now
Read now
Sotirios D Georgopoulos, Vasilios Papastergiou & Stylianos Karatapanis. (2013)
Current options for the treatment of
. Expert Opinion on Pharmacotherapy 14:2, pages 211-223.
Read now
Read now
Articles from other publishers (36)
Rui Zhang, Pengpeng Guo, Jinping Zhou, Peixia Li, Jing Wan, Chunxiao Yang, Jiali Zhou, Yani Liu & Shaojun Shi. (2023) Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers. Scientific Reports 13:1.
Crossref
Crossref
Shuang Zhou, Ran Xie, Xiaodan Zhang, Xu He, Jie Huang, Yin Jungang, Man Liao, Ying Ding, Dandan Yang, Ying Liu, Qian Zhang, Guoping Yang, Fang Liu, Shengjiang Guan, Qing He, Honggang Lou, Fengyun Gong, Xianmin Meng, Qian Xiang, Xia Zhao & Yimin Cui. (2022)
Evaluation of the relationship between polymorphisms in
CYP2C19
and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study
. Clinical and Translational Science 15:6, pages 1439-1448.
Crossref
Crossref
Qiao‐Qiao Shao, Xue‐Chun Yu, Miao Yu, Jing Ma, Jun‐Bo Zhao, Lin Yuan, Ya‐Bin Qi, Ruo‐Bing Hu, Pei‐Ru Wei, Wei Xiao, Ling Lan, Bai‐Ling Jia, Lian‐Zhong Zhang & Song‐Ze Ding. (2022)
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for
Helicobacter pylori
eradication in central China: A single‐center, prospective, open‐label, randomized‐controlled trial
. Helicobacter 27:2.
Crossref
Crossref
Surinder M. Soond & Andrey A. ZamyatninJrJr. (2021) Helicobacter pylori and gastric cancer: a lysosomal protease perspective. Gastric Cancer 25:2, pages 306-324.
Crossref
Crossref
I. B. Angotoeva, N. P. Denisenko, D. A. Sychev, E. V. Schepkina & M. M. Magomedova. (2022) Efficiency of treatment of laryngopharyngeal reflux with proton pump inhibitors depending on the <i>CYP2C19</i> polymorphism. Meditsinskiy sovet = Medical Council:21-2, pages 35-43.
Crossref
Crossref
Chi-Tan Hu. (2022) High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection – A review of the strengths, weaknesses, and proposed solutions. Tzu Chi Medical Journal 34:3, pages 303.
Crossref
Crossref
Jyh‐Chin Yang & John Y. Kao. (2022)
Treatment considerations in
Helicobacter pylori
management
. Alimentary Pharmacology & Therapeutics 55:S1.
Crossref
Crossref
Sairah Hafeez Kamran, Kanwal Rehman, Muhammad Sajid Hamid Akash, Amjad Khan & Ismail Laher. 2022. Biochemistry of Drug Metabolizing Enzymes. Biochemistry of Drug Metabolizing Enzymes
281
304
.
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan & Masoud Keikha. (2021) The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 25, pages 101340.
Crossref
Crossref
Ioana Alexandra Cardos, Dana Carmen Zaha, Rakesh K. Sindhu & Simona Cavalu. (2021) Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 26:19, pages 6078.
Crossref
Crossref
Li-Wei Chen, Liang-Che Chang, Chung-Ching Hua, Ching-Jung Liu, Tien-Shin Chou, Chih-Lang Lin & Rong-Nan Chien. (2021) The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial. Journal of Clinical Medicine 10:19, pages 4352.
Crossref
Crossref
Muhammad Miftahussurur, Dalla Doohan, Ari Fahrial Syam, Iswan Abbas Nusi, Phawinee Subsomwong, Langgeng Agung Waskito, Hasan Maulahela, Fardah Akil, Willy Brodus Uwan, Gontar Siregar, Kartika Afrida Fauzia, Yudith Annisa Ayu Rezkitha, Abdul Rahman, I Dewa Nyoman Wibawa, Alexander Michael Joseph Saudale, Marselino Richardo, Titong Sugihartono, Alvi Chomariyati, Taufan Bramantoro, Tomohisa Uchida & Yoshio Yamaoka. (2021) CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes. Biology 10:4, pages 300.
Crossref
Crossref
Nataliya Pidkovka, Olena Rachkevych & Abbes Belkhiri. (2021) Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers. Oncotarget 12:4, pages 379-391.
Crossref
Crossref
Zeriouh Meriem, Amine Elmekkaoui, Mouna Bouqfar, Abdelkrim Zazour, Wafaa Khannoussi, Ghizlane Kharrasse, Naima Abda & Zahi Ismaili. (2020) Non-Bismuth Quadruple Therapy, Sequential Therapy or High-Dose Esomeprazole and Amoxicillin Dual Therapy for First-Line Helicobacter pylori Eradication: A Prospective Randomized Study. Cureus.
Crossref
Crossref
Basu Dev Banerjee, Ranjeet Kumar, Krishna Latha Thamineni, Harendra Shah, Gaurav Kumar Thakur & Tusha Sharma. (2020) Effect of Environmental Exposure and Pharmacogenomics on Drug Metabolism. Current Drug Metabolism 20:14, pages 1103-1113.
Crossref
Crossref
Hiroshi Matsumoto, Akiko Shiotani & David Y. Graham. 2019. Helicobacter pylori in Human Diseases. Helicobacter pylori in Human Diseases
211
225
.
Bei Tan, Jyh-Chin Yang, Carol L. Young, Shrinivas Bishu, Stephanie Y. Owyang, Mohamad El-Zaatari, Min Zhang, Helmut Grasberger, Jia-ming Qian & John Y. Kao. (2017) Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience. Digestive Diseases and Sciences 63:2, pages 437-445.
Crossref
Crossref
Tomokazu Ohishi, Daniel Ken Inaoka, Kiyoshi Kita & Manabu Kawada. (2018) Dihydroorotate Dehydrogenase as a Target for the Development of Novel <i>Helicobacter pylori</i>-Specific Antimicrobials. Chemical and Pharmaceutical Bulletin 66:3, pages 239-242.
Crossref
Crossref
Zhiqiang Song, Liya Zhou, Jianzhong Zhang, Lihua He, Peng Bai & Yan Xue. (2016) Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Digestive and Liver Disease 48:5, pages 506-511.
Crossref
Crossref
Zhi-Qiang Song, Jian Liu & Li-Ya Zhou. (2016) Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chinese Medical Journal 129:8, pages 992-999.
Crossref
Crossref
Teresa Juárez-Cedillo, Cynthia Martinez-Hernández, Angel Hernández-Constantino, Juan Carlos Garcia-Cruz, Annia M Avalos-Mejia, Luis A. Sánchez-Hurtado, Valentin Islas Perez & Philip D. Hansten. (2016) Clinical Weighting of Drug-Drug Interactions in Hospitalized Elderly. Basic & Clinical Pharmacology & Toxicology 118:4, pages 298-305.
Crossref
Crossref
Yong Hwan Kwon. 2016. Helicobacter pylori. Helicobacter pylori
459
471
.
Jyh-Chin Yang, Chun-Jung Lin, Hong-Long Wang, Jin-De Chen, John Y. Kao, Chia-Tung Shun, Chien-Wei Lu, Bor-Ru Lin, Ming-Jium Shieh, Ming-Chu Chang, Yu-Ting Chang, Shu-Chen Wei, Lin-Chih Lin, Wen-Chun Yeh, Jen-Shin Kuo, Chien-Chih Tung, Yew-Loong Leong, Teh-Hong Wang & Jau-Min Wong. (2015) High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology 13:5, pages 895-905.e5.
Crossref
Crossref
Richard D. Finkelman, Tzung-Dau Wang, Yi Wang, Connie T. Azumaya, Bruce K. Birmingham, Jenny Wissmar & Rogelio Mosqueda-Garcia. (2015) Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects. Clinical Pharmacology in Drug Development 4:1, pages 33-40.
Crossref
Crossref
Chuan Tian, Lixin Zhu, Dan Yu, Zhiwei Cao, Tingguo Kang & Ruixin Zhu. (2014) The Stereoselectivity of CYP2C19 on R- and S-isomers of Proton Pump Inhibitors. Chemical Biology & Drug Design 83:5, pages 610-621.
Crossref
Crossref
Emilia D’Ugo, Serena Rossi & Raffaele De Caterina. (2013) Proton pump inhibitors and clopidogrel: an association to avoid?. Internal and Emergency Medicine 9:1, pages 11-22.
Crossref
Crossref
Vasilios Papastergiou. (2014)
Treatment of
Helicobacter pylori
infection: Meeting the challenge of antimicrobial resistance
. World Journal of Gastroenterology 20:29, pages 9898.
Crossref
Crossref
Ulrich M. Zanger & Matthias Schwab. (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 138:1, pages 103-141.
Crossref
Crossref
Jyh-Chin Yang, Hung-Chih Yang, Chia-Tung Shun, Teh-Hong Wang, Chiang-Ting Chien & John Y. Kao. (2013)
Catechins and Sialic Acid Attenuate
Helicobacter pylori
-Triggered Epithelial Caspase-1 Activity and Eradicate
Helicobacter pylori
Infection
. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-13.
Crossref
Crossref
John Holton. 2013. Genomic and Personalized Medicine. Genomic and Personalized Medicine
914
934
.
Ulrich M. Zanger, Kathrin Klein & Jessica Rieger. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
259
284
.
Alexander V. LyubimovUlrich M. Zanger. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
36
.
Alexander V. LyubimovJoshua G. DeKeyser & Magang Shou. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
38
.
Chia-Hao Chen, Yow-Shieng Uang, Shang-Ta Wang, Jyh-Chin Yang & Chun-Jung Lin. (2012) Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. Evidence-Based Complementary and Alternative Medicine 2012, pages 1-10.
Crossref
Crossref
Martina Teichert, Charlotte van Noord, Andrė G. Uitterlinden, Albert Hofman, Peter N. Buhre, Peter A. G. M. De Smet, Sabine Straus, Bruno H. Ch. Stricker & Loes E. Visser. (2011) Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. British Journal of Haematology 153:3, pages 379-385.
Crossref
Crossref
Jyh‐Chin Yang, Hong‐Long Wang, Herng‐Der Chern, Chia‐Tung Shun, Bor‐Ru Lin, Chun‐Jung Lin & Teh‐Hong Wang. (2012)
Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole‐Amoxicillin Dual Therapy for
Helicobacter pylori
Eradication
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:3, pages 227-238.
Crossref
Crossref